<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="633">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152914</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001444</org_study_id>
    <nct_id>NCT05152914</nct_id>
  </id_info>
  <brief_title>Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2</brief_title>
  <official_title>Intravitreal Enzyme Replacement Therapy to Prevent Retinal Disease Progression in Children With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David L Rogers, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II randomized, masked, clinical trial to determine the safety and efficacy&#xD;
      of intravitreal administration of cerliponase alfa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/II study for 5 subjects receiving an intravitreal injection of cerliponase&#xD;
      alfa under sedation into the proclaimed study eye(s) in a 4-week interval over 24 months.&#xD;
      This study will be monitored by a Data Safety Monitoring Committee (DSMB). Each subject will&#xD;
      participate in the ongoing study for an active period of 2 years. Subjects will then transfer&#xD;
      to a bi-annual monitoring program where data will be collected from bi-annual standard of&#xD;
      care visits for an additional 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>2 years</time_frame>
    <description>Based on the development of unacceptable toxicity, defined as the occurrence of any Grade 3 or higher, unanticipated, treatment related toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of intravitreal cerliponase alfa to stabilize retinal architecture.</measure>
    <time_frame>2 years</time_frame>
    <description>Efficacy will be determined by measuring central retinal thickness via OCT imaging prior to each injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of intravitreal cerliponase alfa to stabilize fundoscopic features.</measure>
    <time_frame>2 years</time_frame>
    <description>Efficacy will be determined by measuring the Weill Cornell LINCL Ophthalmic Severity Score prior to each injection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Neuronal Ceroid Lipofuscinosis Type 2</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerliponase Alfa</intervention_name>
    <description>Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Brineura</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genotypic confirmation of classical CLN2 Batten's disease from a CLIA certified lab.&#xD;
&#xD;
          -  Enzyme level deficiency of tripeptidyl-peptidase&#xD;
&#xD;
          -  Minimum age requirement: 24 months of age at enrollment&#xD;
&#xD;
          -  Maximum age requirement: 72 months of age at enrollment&#xD;
&#xD;
          -  Currently receiving intraventricular cerliponase alfa&#xD;
&#xD;
          -  Willing to participate in the proposed study visits over the 2-year period&#xD;
&#xD;
          -  Minimum central retinal thickness (CRT) of 140μm based upon OCT assessment&#xD;
&#xD;
          -  Clear ocular media&#xD;
&#xD;
          -  No ocular pathology present to account for vision loss other than optic atrophy and&#xD;
             pigmentary retinopathy that is felt to be due to the CLN2 disease process&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any opacities in the clear ocular media including vitreous debris.&#xD;
&#xD;
          -  History of ocular trauma or prior ocular surgery.&#xD;
&#xD;
          -  Episode of generalized motor status epilepticus within four weeks before the First&#xD;
             Dose visit&#xD;
&#xD;
          -  Severe infection (e.g., upper respiratory tract infection, pneumonia, pyelonephritis,&#xD;
             or meningitis) within four weeks before the First Dose visit (enrollment may be&#xD;
             postponed)&#xD;
&#xD;
          -  Those with a history of bleeding disorders.&#xD;
&#xD;
          -  History of or current chemotherapy, radiotherapy or other immunosuppression therapy&#xD;
             within the past 30 days (corticosteroid treatment may be permitted at the discretion&#xD;
             of the PI)&#xD;
&#xD;
          -  Has a medical condition, or extenuating circumstance that, in the opinion of the&#xD;
             investigator, might compromise the subject's ability to comply with the protocol&#xD;
             required testing or procedures or compromise the subject's wellbeing, safety, or&#xD;
             clinical interpretability&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>72 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Rogers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R. NCL diseases - clinical perspectives. Biochim Biophys Acta. 2013 Nov;1832(11):1801-6. doi: 10.1016/j.bbadis.2013.04.008. Epub 2013 Apr 17.</citation>
    <PMID>23602993</PMID>
  </reference>
  <reference>
    <citation>Sleat DE, Donnelly RJ, Lackland H, Liu CG, Sohar I, Pullarkat RK, Lobel P. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science. 1997 Sep 19;277(5333):1802-5.</citation>
    <PMID>9295267</PMID>
  </reference>
  <reference>
    <citation>Schulz A, Ajayi T, Specchio N, de Los Reyes E, Gissen P, Ballon D, Dyke JP, Cahan H, Slasor P, Jacoby D, Kohlschütter A; CLN2 Study Group. Study of Intraventricular Cerliponase Alfa for CLN2 Disease. N Engl J Med. 2018 May 17;378(20):1898-1907. doi: 10.1056/NEJMoa1712649. Epub 2018 Apr 24.</citation>
    <PMID>29688815</PMID>
  </reference>
  <reference>
    <citation>Gardner E, Bailey M, Schulz A, Aristorena M, Miller N, Mole SE. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease. Hum Mutat. 2019 Nov;40(11):1924-1938. doi: 10.1002/humu.23860. Epub 2019 Jul 26.</citation>
    <PMID>31283065</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>David L Rogers, MD</investigator_full_name>
    <investigator_title>Chief of the Department of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

